A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

Kennedy Jr. threatened to bar NIH scientists from publishing in leading medical journals, saying the New England Journal of ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

The FDA has approved the first at-home cervical cancer test and weight loss drugs could reduce obesity related cancers.

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Popular GLP-1 weight-loss drugs like Ozempic and Zepbound can help reduce a woman's risk for as many as 14 cancers associated ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...